With already five EGFR TKIs to choose from, is there room for one more? Janssen thinks there is, betting on a combination strategy to defeat osimertinib
Approval based on the NSCLC cohorts included in the ARROW phase 1/2 study. Data from thyroid cancer cohorts has been filed; PDUFA in February 2021
